[1] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma:an update [J]. Hepatology,2011,53(3):1020-1022.
[2] 武永乐,李 冰,刘 晖, 等. GPC3对AFP阴性乙型肝炎病毒相关肝细胞癌的诊断价值[J].北京医学,2013,35(6):416-419.
[3] 陈 洁,姚 敏,姚登福.磷脂酰肌醇蛋白多糖-3介导的信号通路与肝癌靶向治疗[J]. 临床肝胆病杂志,2013,29(1):77-80.
[4] 郑联坵,魏开鹏,潘兴南,等. 血清高尔体蛋白73诊断肝细胞癌价值探讨[J].实用肝脏病杂志,2013,18(5):407-410.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
[6] 翁彭剑,高园生,鲁姣英,等. 检测血清GP73对PHC诊断价值的探讨[J].中国卫生检验杂志,2011,21(8):1971-1973.
[7] 朱 凡,沈世强,柯章明.中晚期肝癌患者综合治疗的临床观察[J].中国肿瘤临床与康复,2013,20(6):569-571.
[8] Ba MC,Long H, Tang YQ, et al. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review[J]. Int J Clin Exp Pathol,2012,5(9):874-881.
[9] Marrero JA, Romano PR, Nikolaeva O,et al. GP73, a resident Golgi glycoprotion, is a novel serum marker for hepatocelluar carcinoma[J]. J Hepatol,2005,43(6):1007-1012.
[10] Kladney RD, Bulla GA,Guo L,et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene,2000,249(1-2):53-65.
[11] Kladney RD,Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrame protein,in viral and nonviral liver disease[J]. Hepatology,2002,35(6):1431-1440.
[12] Mao YL, Yang HY, Xu HF, et al. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma:a primary study[J]. Zhonghua Yi Xue Za Zhi,2008,88(14):948-951.
[13] Hu JS, Wu DW, Liang S, et al. GP73, a resident Golgi glycoprotein, is sensibility and speecificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population[J]. Med Oncol,2010,27(2):339-345.
[14] 李继荣. 血清高尔基体蛋白73对原发性肝癌的早期诊断价值探讨[J].检验医学,2013,28(2):166-167.
[15] 杨 颖,肖 蕾,毛 睿,等.高尔基体糖蛋白73的表达特征及其对肝癌与肝硬化的鉴别诊断价值[J].中华肝脏病杂志,2012,20(12):920-924.
[16] Tian L, Wang Y, Xu D, et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases[J]. Int J Cancer,2011,129(8): 1923-1931.
[17] Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy [J]. Eur J Cancer, 2011, 47(3):333-338.
[18] Liu S, Li Y, Chen W, Zheng P, et al. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun,2012,419(4):656-661.
[19] Nobuoka D, Motomura Y, Shirakawa H, et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes[J]. Int J Oncol, 2012, 40(1):63-70.
[20] 江 枫,肖明兵, 倪润洲,等.血清glypican 3 ELISA检测法的建立及初步应用[J].临床检验杂志,2011,29(4):244-246.
[21] Yao M, Yao DF, Bian YZ, et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int,2011,10(3):289-294.
[22] Wang Y, Yang H, Xu H, et al. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-fetoprotein for hepatocelluar carcinoma diagnosis[J]. J Gastroenterol Hepatol, 2014,29(3): 597-602.
[23] 谢明水,刘 杨,陈丹丹,等. AFP-L3、GP73、GPC3联合检测在原发性肝癌诊断中的应用价值[J]. 国际检验医学杂志,2004,26(5):519-520.
[24] Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J]. J Gastroenterol, 2010, 45(12):1272-1282. |